Androgen deprivation therapy represents an important part of the management of prostate cancer.
However, epidemiological data have shown that it is a well-established cause of osteoporosis and increased risk of fracture. So far no consensus guidelines have been published regarding the screening and treatment of osteoporosis in men with prostate cancer. Here we report the design of a new questionnaire, derived from the FRAX(®) ("Fracture Risk Assessment Tool") algorithm, to evaluate the risk of fracture in those patients. In accordance with recent reviews and on the basis of their experience, our French board of experts recommends systematic screening for osteoporosis with dual energy x- ray absorptiometry scans, practice of exercise and calcium and vitamin D supplementation, and selective treatment with bisphosphonates in men at greatest osteoporotic risk.
Written by:
Cortet B, Lartigau E, Caty A, Moulinier F, Staerman F, Villamizar-Vesga J, Villers A. Are you the author?
Service de Rhumatologie, Centre Hospitalier Universitaire, 59000 Lille, France.
Reference: Prog Urol. 2012 Sep;22 Suppl 2:S31-8.
doi: 10.1016/S1166-7087(12)70034-9
PubMed Abstract
PMID: 23098788
Article in French.
UroToday.com Prostate Cancer Section
